AU2004251104B2 - N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors - Google Patents
N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors Download PDFInfo
- Publication number
- AU2004251104B2 AU2004251104B2 AU2004251104A AU2004251104A AU2004251104B2 AU 2004251104 B2 AU2004251104 B2 AU 2004251104B2 AU 2004251104 A AU2004251104 A AU 2004251104A AU 2004251104 A AU2004251104 A AU 2004251104A AU 2004251104 B2 AU2004251104 B2 AU 2004251104B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- ring
- compound according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301922-1 | 2003-06-27 | ||
| SE0301922A SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Novel compounds |
| PCT/GB2004/002702 WO2005000822A1 (en) | 2003-06-27 | 2004-06-23 | N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004251104A1 AU2004251104A1 (en) | 2005-01-06 |
| AU2004251104B2 true AU2004251104B2 (en) | 2008-05-08 |
Family
ID=27656653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004251104A Ceased AU2004251104B2 (en) | 2003-06-27 | 2004-06-23 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7485644B2 (OSRAM) |
| EP (1) | EP1644340B1 (OSRAM) |
| JP (1) | JP4701167B2 (OSRAM) |
| KR (1) | KR20060026440A (OSRAM) |
| CN (2) | CN102229589A (OSRAM) |
| AR (1) | AR044931A1 (OSRAM) |
| AT (1) | ATE414063T1 (OSRAM) |
| AU (1) | AU2004251104B2 (OSRAM) |
| BR (1) | BRPI0411929A (OSRAM) |
| CA (1) | CA2529468A1 (OSRAM) |
| CO (1) | CO5650254A2 (OSRAM) |
| CY (1) | CY1108757T1 (OSRAM) |
| DE (1) | DE602004017733D1 (OSRAM) |
| DK (1) | DK1644340T3 (OSRAM) |
| ES (1) | ES2315675T3 (OSRAM) |
| HR (1) | HRP20090009T3 (OSRAM) |
| IL (1) | IL172615A0 (OSRAM) |
| IS (1) | IS8257A (OSRAM) |
| MX (1) | MXPA05013460A (OSRAM) |
| MY (1) | MY138680A (OSRAM) |
| NO (1) | NO20060444L (OSRAM) |
| NZ (1) | NZ544208A (OSRAM) |
| PL (1) | PL1644340T3 (OSRAM) |
| PT (1) | PT1644340E (OSRAM) |
| RU (1) | RU2351595C2 (OSRAM) |
| SA (1) | SA04250224B1 (OSRAM) |
| SE (1) | SE0301922D0 (OSRAM) |
| SI (1) | SI1644340T1 (OSRAM) |
| TW (1) | TW200524898A (OSRAM) |
| UA (1) | UA81491C2 (OSRAM) |
| UY (1) | UY28387A1 (OSRAM) |
| WO (1) | WO2005000822A1 (OSRAM) |
| ZA (1) | ZA200510458B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| RS52229B (sr) * | 2005-10-26 | 2012-10-31 | Merck Serono Sa. | Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza |
| CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| KR101822444B1 (ko) * | 2010-07-08 | 2018-01-26 | 가켄 세이야쿠 가부시키가이샤 | N-히드록시포름아미드 유도체 및 그를 함유하는 의약 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038843A1 (en) * | 1998-01-30 | 1999-08-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| WO2000012478A1 (en) * | 1998-08-31 | 2000-03-09 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| WO2000075108A1 (en) * | 1999-06-04 | 2000-12-14 | Astrazeneca Uk Limited | Inhibitors of metalloproteinases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02008111A (es) * | 2000-02-21 | 2002-11-29 | Astrazeneca Ab | N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas. |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| BR0309671A (pt) * | 2002-04-25 | 2005-05-03 | Pharmacia Corp | ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease |
| JP2006527754A (ja) * | 2003-06-19 | 2006-12-07 | セルテック アール アンド ディ リミテッド | Ｃｄ２３分断阻害物質としてのヒドロキサム酸スルホンアミド |
-
2003
- 2003-06-27 SE SE0301922A patent/SE0301922D0/xx unknown
-
2004
- 2004-06-23 NZ NZ544208A patent/NZ544208A/en unknown
- 2004-06-23 DE DE602004017733T patent/DE602004017733D1/de not_active Expired - Lifetime
- 2004-06-23 DK DK04743053T patent/DK1644340T3/da active
- 2004-06-23 CA CA002529468A patent/CA2529468A1/en not_active Abandoned
- 2004-06-23 PL PL04743053T patent/PL1644340T3/pl unknown
- 2004-06-23 PT PT04743053T patent/PT1644340E/pt unknown
- 2004-06-23 ES ES04743053T patent/ES2315675T3/es not_active Expired - Lifetime
- 2004-06-23 WO PCT/GB2004/002702 patent/WO2005000822A1/en not_active Ceased
- 2004-06-23 MX MXPA05013460A patent/MXPA05013460A/es active IP Right Grant
- 2004-06-23 EP EP04743053A patent/EP1644340B1/en not_active Expired - Lifetime
- 2004-06-23 AU AU2004251104A patent/AU2004251104B2/en not_active Ceased
- 2004-06-23 HR HR20090009T patent/HRP20090009T3/xx unknown
- 2004-06-23 RU RU2005141058/04A patent/RU2351595C2/ru not_active IP Right Cessation
- 2004-06-23 AT AT04743053T patent/ATE414063T1/de active
- 2004-06-23 JP JP2006516467A patent/JP4701167B2/ja not_active Expired - Fee Related
- 2004-06-23 CN CN201110103041XA patent/CN102229589A/zh active Pending
- 2004-06-23 SI SI200430979T patent/SI1644340T1/sl unknown
- 2004-06-23 BR BRPI0411929-0A patent/BRPI0411929A/pt not_active IP Right Cessation
- 2004-06-23 UA UAA200511723A patent/UA81491C2/uk unknown
- 2004-06-23 CN CN2004800182447A patent/CN1812974B/zh not_active Expired - Fee Related
- 2004-06-23 US US10/561,747 patent/US7485644B2/en not_active Expired - Fee Related
- 2004-06-23 KR KR1020057024709A patent/KR20060026440A/ko not_active Abandoned
- 2004-06-25 TW TW093118692A patent/TW200524898A/zh unknown
- 2004-06-25 UY UY28387A patent/UY28387A1/es unknown
- 2004-06-25 MY MYPI20042517A patent/MY138680A/en unknown
- 2004-06-25 AR ARP040102258A patent/AR044931A1/es not_active Application Discontinuation
- 2004-07-14 SA SA04250224A patent/SA04250224B1/ar unknown
-
2005
- 2005-12-15 IL IL172615A patent/IL172615A0/en unknown
- 2005-12-22 ZA ZA200510458A patent/ZA200510458B/xx unknown
- 2005-12-27 CO CO05130352A patent/CO5650254A2/es not_active Application Discontinuation
-
2006
- 2006-01-23 IS IS8257A patent/IS8257A/is unknown
- 2006-01-27 NO NO20060444A patent/NO20060444L/no not_active Application Discontinuation
-
2009
- 2009-01-19 CY CY20091100064T patent/CY1108757T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038843A1 (en) * | 1998-01-30 | 1999-08-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| WO2000012478A1 (en) * | 1998-08-31 | 2000-03-09 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| WO2000075108A1 (en) * | 1999-06-04 | 2000-12-14 | Astrazeneca Uk Limited | Inhibitors of metalloproteinases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101541789B (zh) | 用作基质金属蛋白酶抑制剂的乙内酰脲衍生物 | |
| US20110124619A1 (en) | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | |
| US7598242B2 (en) | Compounds for the treatment of inflammatory disorders | |
| US8129412B2 (en) | Hydantoin derivatives useful as metalloproteinase inhibitors | |
| EP1644340B1 (en) | N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors | |
| HK1086835B (en) | N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors | |
| HK1108435B (en) | Hydantoin derivatives useful as metalloproteinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |